MAYNF (Mayne Pharma Group) Moat Score: 4/10 (As of Jun. 29, 2026)


MAYNF Mayne Pharma Group Ltd MAYNF
43 GF Score
Price $1.65
GF Value $3.41
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group Moat Score?

Mayne Pharma Group MAYNF 43 Moat Score is 4 as of Jun. 29, 2026. GuruFocus rates MAYNF with a GF Score™ of 43/100 and a GF Value™ of $3.41 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 119 Medical Distribution companies, Mayne Pharma Group ranks better than 89.92% on this metric.

Mayne Pharma Group has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Mayne Pharma Group has Narrow Moat: Mayne Pharma Group Ltd has a modest moat due to its portfolio of generic pharmaceuticals and some regulatory barriers. However, intense competition and limited brand strength constrain its ability to achieve a wider moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Mayne Pharma Group might have Narrow Moat - Discernible but modest moat.

Mayne Pharma Group  (OTCPK:MAYNF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Mayne Pharma Group Moat Score Related Terms

MAYNF vs MCK, CAH, COR: Moat Score Comparison

For the Medical Distribution subindustry, Mayne Pharma Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mayne Pharma Group Moat Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Moat Score distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Moat Score falls into.


MAYNF
43GF Score
Mayne Pharma Group Ltd MAYNF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Mayne Pharma Group (MAYNF) has a Moat Score of 4 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Mayne Pharma Group ranks #12 out of 119 companies in the Medical Distribution industry, placing it in the top 10.1%.
Is Mayne Pharma Group's Moat Score too high?
Mayne Pharma Group's current Moat Score is 4. Based on the distribution chart, Mayne Pharma Group ranks #12 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Moat Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #12 out of 119 companies for Moat Score. This places Mayne Pharma Group in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Distribution company?
A good Moat Score depends on the Medical Distribution industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Mayne Pharma Group's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.41, compared to a current price of $1.65 — trading 51.6% below its estimated fair value. The current Moat Score is 4. Mayne Pharma Group's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Moat Score is 4 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayne Pharma Group (MAYNF) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of $1.65 is trading 51.6% below its estimated GF Value™ of $3.41. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for MAYNF:

  • Moat Score: 4
  • GF Value™: $3.41 vs. price of $1.65 (51.6% below fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mayne Pharma Group Business Description

Other Exchanges MYX:Australia
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
43GF Score

Get the complete analysis for MAYNF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$3.41
GF Value